Clinical Trials Browser

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT04172532 2026-04-13

Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

Phase 1/2 Recruiting

92 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT04548752 2026-04-13

Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations

Phase 2 Active not recruiting

88 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT04550494 2026-04-13

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Phase 2 Recruiting

36 enrolled

BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms

NCT05411094 2026-04-13

Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer

Phase 1 Recruiting

18 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT05554367 2026-04-13

Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial

Phase 2 Active not recruiting

199 enrolled

GastrointestinalGynecologic

Ovarian Neoplasms, Pancreatic Neoplasms

NCT06454383 2026-04-13

Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer

Phase 1 Recruiting

19 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT06958328 2026-04-08

LAP100

Phase 3 Recruiting

356 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT04239573 2026-03-23

Comparing Two Methods to Follow Patients With Pancreatic Cysts

Phase NA Active not recruiting

4,606 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT05961982 2026-03-23

ERASE

Phase NA Recruiting

84 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT07089940 2026-03-23

OMO-103 for the Treatment of Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma

Phase EARLY_PHASE1 Recruiting

12 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT04975516 2026-03-03

Standard of Care Chemotherapy With or Without Stereotactic Body Radiation Therapy for Oligometastatic Pancreatic Cancer

Phase 2 Terminated

3 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT06906562 2026-02-17

A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations

Phase 2 Recruiting

40 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT07214298 2026-02-06

Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma

Phase 1/2 Recruiting

35 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT06381154 2026-01-30

Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer

Phase 2 Recruiting

25 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT04673448 2026-01-09

Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer

Phase 1 Active not recruiting

18 enrolled

BreastGastrointestinalGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms

NCT06073431 2026-01-09

LOTUS

Recruiting

800 enrolled

GastrointestinalThoracic

Lung Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT06115499 2026-01-07

The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer

Phase 2/3 Active not recruiting

10 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT06626256 2025-12-24

STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma

Phase 1 Withdrawn

DermatologicGastrointestinalGenitourinaryGynecologic

Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms

NCT07226856 2025-12-22

BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma

Phase 2 Recruiting

43 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT04858009 2025-12-16

Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pancreatic Cancer and Peritoneal Metastasis

Phase 2 Recruiting

40 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT02293954 2025-11-14

Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer

Phase NA Active not recruiting

20 enrolled 8 charts

BreastGastrointestinalThoracic

Bile Duct Neoplasms, Breast Neoplasms, Colonic Neoplasms, Gallbladder Neoplasms, Gastrointestinal Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Rectal Neoplasms, Carcinoma, Medullary

NCT04821284 2025-11-04

Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer

Phase 1/2 Active not recruiting

120 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT05518903 2025-10-02

Investigational Scan (68Ga-FAPI-46 PET/CT) for Imaging of Cancer-Associated Fibroblasts for Localized Pancreatic Ductal Adenocarcinoma

Phase 2 Recruiting

130 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT04147494 2025-08-12

Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues

Phase EARLY_PHASE1 Active not recruiting

29 enrolled

BreastGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Carcinoma, Renal Cell, Colonic Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms

NCT07118176 2025-08-12

Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers

Phase 1 Recruiting

30 enrolled

BreastCNSEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckNETSarcomaThoracic

Adrenal Gland Neoplasms, Anus Neoplasms, Urinary Bladder Neoplasms, Brain Neoplasms, Breast Neoplasms, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Penile Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Stomach Neoplasms, Testicular Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Vaginal Neoplasms, Colorectal Neoplasms, Carcinoma, Medullary, Cholangiocarcinoma, Neuroendocrine Tumors, Solitary Fibrous Tumors

NCT06549725 2025-08-01